Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study

Abstract

BackgroundThere is an obvious need to identify biomarkers that could predict patient response to an osteoarthritis (OA) treatment. This post hoc study explored in a 2-year randomized controlled trial in patients with knee OA, the likelihood of some serum biomarkers to be associated with a better response to chondroitin sulfate in reducing cartilage volume loss.MethodsEight biomarkers were studied: hyaluronic acid (HA), C reactive protein (CRP), adipsin, leptin, N-terminal propeptide of collagen IIα (PIIANP), C-terminal crosslinked telopeptide of type I collagen (CTX-1), matrix metalloproteinase-1 (MMP-1), and MMP-3. Patients were treated with chondroitin sulfate (1200 mg/day; n = 57) or celecoxib (200 mg/day; n = 62). Serum biomarkers were measured at baseline. The cartilage volume at baseline and its loss at 2 years were assessed by quantitative magnetic resonance imaging (MRI). Statistical analysis included analysis of covariance.ResultsAs data from the original MOSAIC trial showed no differences in cartilage volume and loss in the lateral compartment of the knee joint between the two treatment groups in any comparison, only the medial compartment and its subregions were studied. Stratification according to the median biomarker levels was used to discriminate treatment effect. In patients with levels of biomarkers of inflammation (HA, leptin and adipsin) lower than the median, those treated with chondroitin sulfate demonstrated less cartilage volume loss in the medial compartment, condyle, and plateau (p ≤ 0.047). In contrast, patients treated with chondroitin sulfate with higher levels of MMP-1 and MMP-3, biomarkers of cartilage catabolism, had less cartilage volume loss in the medial compartment, condyle, and plateau (p ≤ 0.050). Patients with higher levels of PIIANP and CTX-1, biomarkers related to collagen anabolism and bone catabolism, respectively, had reduced cartilage volume loss in the medial condyle (p ≤ 0.026) in the chondroitin sulfate group.ConclusionThis study is suggestive of a potentially greater response to chondroitin sulfate treatment on cartilage volume loss in patients with knee OA with low level of inflammation and/or greater level of cartilage catabolism.Trial registrationThis is a post hoc study. Original trial registration: ClinicalTrials.gov, NCT01354145. Registered on 13 May 2011. Electronic supplementary materialThe online version of this article (doi:10.1186/s13075-017-1377-y) contains supplementary material, which is available to authorized users.

Strawberries Improve Pain and Inflammation in Obese Adults with Radiographic Evidence of Knee Osteoarthritis

“…Metalloproteinases zinc-dependent enzymes (MMPs) play a key role in extracellular matrix remodeling and cartilage metabolism in knee OA. Among the various isoforms of MMPs, MMP-3 plays an important role in cartilage degradation, and has been shown to be responsive to therapeutic agents in patients with various stages of OA [ 12 , 45 , 46 ]. On the other hand, MMP-8 has been implicated in the degradation of already compromised cartilage matrix, and a few clinical studies have examined its response to therapeutic agents, and revealed conflicting results [ 45 , 47 , 48 ].…”

Osteoarthritis year in review 2018: biomarkers (biochemical markers)

“…In a post-hoc study explored in a 2-year RCT of KOA patients, some serum biomarkers were found to be associated with a better response to chondroitin sulfate (CS) in reducing cartilage volume loss. The results suggested a greater response to CS treatment on cartilage volume loss in KOA patients with low level of inflammation (HA, leptin and adipsin) and/or greater level of cartilage catabolism (PIIANP, CTX-I, MMP-1, MMP-3) 45 . In another study, serum biomarker phenotypes associated with the occurrence of all-cause TJR were retrospectively explored using data from a phase III trial of tanezumab 46 .…”

Suppression of KCNQ/M Potassium Channel in Dorsal Root Ganglia Neurons Contributes to the Development of Osteoarthritic Pain

“…Osteoarthritis (OA) is recognized by the degeneration of articular cartilage, changes in the subchondral bone, inactivity-related stiffness, and chronic pain [1]. OA constitutes one of the largest cost burdens to healthcare with pain being the dominant symptom and reason for clinical presentation [2].…”